Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Caribou Biosciences (CRBU – Research Report) today and set a price target of $24.00. The company’s shares closed last Friday at $6.28.
R. Cann covers the Healthcare sector, focusing on stocks such as Moderna, Caribou Biosciences, and MEI Pharma. According to TipRanks, R. Cann has an average return of -2.0% and a 38.62% success rate on recommended stocks.
Currently, the analyst consensus on Caribou Biosciences is a Strong Buy with an average price target of $26.80.
See today’s best-performing stocks on TipRanks >>
Based on Caribou Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.3 million and a GAAP net loss of $26.65 million. In comparison, last year the company earned a revenue of $3.98 million and had a GAAP net loss of $20.97 million
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is neutral on the stock. Last month, Kanner Steven, the CSO of CRBU bought 21,401.00 shares for a total of $57,568.69.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
Read More on CRBU:
- Caribou Biosciences reports CB-010 ANTLER Phase 1 trial progress
- Caribou Biosciences selects ROR1 as target for CB-020
- Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
- Oppenheimer emerging biotech analysts to hold analyst/industry conference call
- Caribou Biosciences announces FDA granted RMAT, FTD to CB-010
